Skip to content

Observational study to investigate the effects of prostaglandin analogue-induced improved retinal blood flow on the development of visual field damage in patients with preperimetric glaucoma

Observational study to investigate the effects of prostaglandin analogue-induced improved retinal blood flow on the development of visual field damage in patients with preperimetric glaucoma - Pathological study in preperimetric glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000013733
Enrollment
200
Registered
2014-04-16
Start date
2012-08-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

None listed

Sponsors

Santen Pharmaceutical Co., Ltd.
Lead Sponsor
Medical Software Development Co., Ltd. AC MEDICAL INC. Softcare Ltd. Medical TOUKEI Corp.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1 Patients able to visit the medical institution at pre-defined visits as instructed by the physician, who are willing to participate in the study, and who are able to provide written informed consent 2 Patients requiring treatment as assessed by the physician 3 Patients with intraocular pressure of 21mmHg or lower, with observed retinal thinning, but without visual field damage 4 Patients with Grade 3 or 4 angles according to the Shaffer classification

Exclusion criteria

Exclusion criteria: Patients assessed as inappropriate to be enrolled in this observational study by the physician

Design outcomes

Primary

MeasureTime frame
Onset of visual field abnormal

Countries

Japan

Contacts

Public ContactNaoko Aizawa

Tohoku Univ. Hospital Ophthalmology

n.aizawa@oph.med.tohoku.ac.jp022-717-7294

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026